Key result
Amyloid and tau biomarkers become increasingly abnormal from subjective cognitive impairment to Alzheimer's disease and may help identify individuals who will cognitively decline.
Why the study?
Can amyloid and tau biomarkers differentiate individuals with subjective cognitive impairment from healthy controls or predict cognitive decline?
Can amyloid and tau biomarkers differentiate individuals with subjective cognitive impairment from healthy controls or predict cognitive decline?
Amyloid and tau biomarkers may help identify individuals with subjective cognitive impairment who are at risk for future cognitive decline, though they cannot differentiate SCI from healthy controls.
Answers are grounded in this paper and cite their sources.
May aid risk stratification in subjective cognitive impairment but should not yet change practice; leaves open need for prospective validation.
Subjective cognitive impairment (SCI) refers to concerns regarding one's cognitive functioning in the absence of objective evidence of impairment, and may represent an early stage of Alzheimer's disease. However, as not all individuals with SCI cognitively decline, there is growing interest in the early identification of those individuals with SCI who are most at risk of developing Alzheimer's disease. One promising method of early identification involves the use of biomarkers that are known to be associated with the pathophysiology of the disease; in particular, markers of amyloid and tau accumulation. While there has been substantial research on amyloid and tau biomarkers in the context of mild cognitive impairment (MCI), only recently has attention shifted to SCI, which may represent an even earlier stage in the disease course. The purpose of this paper is to qualitatively review the literature on amyloid and tau biomarkers in SCI. A brief discussion of non-amyloid/tau biomarkers is also included. Not surprisingly, we found that amyloid and tau biomarker profiles become increasingly abnormal from SCI, to MCI, to Alzheimer's disease. Additionally, although amyloid and tau biomarkers appear to be unable to differentiate between SCI and healthy controls, there is some evidence to suggest that they may be able to differentiate between those individuals with SCI who cognitively decline over time and those who do not. While this finding has potential clinical implications, achieving optimal predictive value will likely require further research into the use of numerous biomarkers in combination.
No takes yet. Share an insight, caveat, or question.
Colijn et al. (2015) conducted a review in Subjective cognitive impairment (SCI). Amyloid and tau biomarkers vs. Healthy controls was evaluated. Amyloid and tau biomarkers become increasingly abnormal from subjective cognitive impairment to Alzheimer's disease and may help identify individuals who will cognitively decline.
Synapse has enriched 10 related papers. Consider them for comparative context: